Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

MyNCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

62 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Direct transition to long-acting risperidone--analysis of long-term efficacy.
Kissling W, Heres S, Lloyd K, Sacchetti E, Bouhours P, Medori R, Llorca PM. Kissling W, et al. Among authors: Heres S. J Psychopharmacol. 2005 Sep;19(5 Suppl):15-21. doi: 10.1177/0269881105056514. J Psychopharmacol. 2005. PMID: 16144782 Clinical Trial.
Why olanzapine beats risperidone, risperidone beats quetiapine, and quetiapine beats olanzapine: an exploratory analysis of head-to-head comparison studies of second-generation antipsychotics.
Heres S, Davis J, Maino K, Jetzinger E, Kissling W, Leucht S. Heres S, et al. Am J Psychiatry. 2006 Feb;163(2):185-94. doi: 10.1176/appi.ajp.163.2.185. Am J Psychiatry. 2006. PMID: 16449469 Review.
The authors reviewed results of head-to-head studies of second-generation antipsychotics funded by pharmaceutical companies to determine if a relationship existed between the sponsor of the trial and the drug favored in the study's overall outcome. ...Two authors who were not blinded to the study sponsor reviewed the entire report of each study for sources of bias that could have affected the results in favor of the sponsor's drug. ...
The authors reviewed results of head-to-head studies of second-generation antipsychotics funded by pharmaceutical companies to determine if …
The attitude of patients towards antipsychotic depot treatment.
Heres S, Schmitz FS, Leucht S, Pajonk FG. Heres S, et al. Int Clin Psychopharmacol. 2007 Sep;22(5):275-82. doi: 10.1097/YIC.0b013e3280c28424. Int Clin Psychopharmacol. 2007. PMID: 17690596
A frequently stated reason is the patient's objection to depot treatment. We questioned 300 patients in nine psychiatric hospitals shortly before their discharge about their preferences in the mode of administration of antipsychotic treatment, taking earlier depot experience into account. 145 patients were naive to depot treatment, 95 had experienced a depot earlier and 60 were currently on a depot medication. ...Preference of depots as favorable antipsychotic treatment depends on the patient's experience with the formulation. A considerable number of patients would accept a depot drug as a long-term treatment option. ...
A frequently stated reason is the patient's objection to depot treatment. We questioned 300 patients in nine psychiatric hospitals sh …
Methodological issues in current antipsychotic drug trials.
Leucht S, Heres S, Hamann J, Kane JM. Leucht S, et al. Among authors: Heres S. Schizophr Bull. 2008 Mar;34(2):275-85. doi: 10.1093/schbul/sbm159. Epub 2008 Jan 29. Schizophr Bull. 2008. PMID: 18234700 Free PMC article. Review.
DRD4 48 bp VNTR but not 5-HT 2C Cys23Ser receptor polymorphism is related to antipsychotic-induced weight gain.
Popp J, Leucht S, Heres S, Steimer W. Popp J, et al. Among authors: Heres S. Pharmacogenomics J. 2009 Feb;9(1):71-7. doi: 10.1038/tpj.2008.5. Epub 2008 Mar 11. Pharmacogenomics J. 2009. PMID: 18332898 Clinical Trial.
Concerning the DRD4 48 bp VNTR polymorphism the increase in body mass index was significantly less in group 1 (0.38 kg m(-2); s.d.=1.04) than in group 2 (0.89 kg m(-2); s.d.=1.23; P=0.003). ...
Concerning the DRD4 48 bp VNTR polymorphism the increase in body mass index was significantly less in group 1 (0.38 kg m(-2); s.d.=1. …
62 results
Jump to page
Feedback